Canada - English - Health Canada

bavarian nordic as - inactivated rabies virus (flury lep) - powder for solution - 2.5unit - inactivated rabies virus (flury lep) 2.5unit - vaccines

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - hepatitis a virus strain hm175 antigen (formaldehyde inactivated) (unii: 5bfc8lz6lq) (hepatitis a virus strain hm175 antigen (formaldehyde inactivated) - unii:5bfc8lz6lq) - hepatitis a virus strain hm175 antigen (formaldehyde inactivated) 1440 [iu] in 1 ml - havrix® is indicated for active immunization against disease caused by hepatitis a virus (hav). havrix is approved for use in persons 12 months of age and older. primary immunization should be administered at least 2 weeks prior to expected exposure to hav. severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis a-containing vaccine, or to any component of havrix, including neomycin, is a contraindication to administration of havrix [see description (11)] . pregnancy category c animal reproduction studies have not been conducted with havrix. it is also not known whether havrix can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. havrix should be given to a pregnant woman only if clearly needed. it is not known whether havrix is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when havrix is administered to a nursing woman. the safety and effectiveness of havrix, doses of 360 el.u. or 720 e

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - hepatitis a virus strain hm175 antigen (formaldehyde inactivated) (unii: 5bfc8lz6lq) (hepatitis a virus strain hm175 antigen (formaldehyde inactivated) - unii:5bfc8lz6lq) - hepatitis a virus strain hm175 antigen (formaldehyde inactivated) 1440 [iu] in 1 ml - havrix® is indicated for active immunization against disease caused by hepatitis a virus (hav). havrix is approved for use in persons 12 months of age and older. primary immunization should be administered at least 2 weeks prior to expected exposure to hav. severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis a-containing vaccine, or to any component of havrix, including neomycin, is a contraindication to administration of havrix [see description (11)] . pregnancy category c animal reproduction studies have not been conducted with havrix. it is also not known whether havrix can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. havrix should be given to a pregnant woman only if clearly needed. it is not known whether havrix is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when havrix is administered to a nursing woman. the safety and effectiveness of havrix, doses of 360 el.u. or 720 e

Austria - English - HMA (Heads of Medicines Agencies)

pfizer limited - leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - rabies virus + leptospira

Germany - English - HMA (Heads of Medicines Agencies)

pfizer limited - leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - rabies virus + leptospira

France - English - HMA (Heads of Medicines Agencies)

pfizer limited - leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - rabies virus + leptospira

Portugal - English - HMA (Heads of Medicines Agencies)

pfizer limited - leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - rabies virus + leptospira

Kenya - English - Pharmacy and Poisons Board

glaxosmithkline pharmaceuticals kenya ltd likoni road, p.o. box 78392, 00507, nairobi, kenya - inactivated rabies virus (strain flury lep) - powder and solvent for solution for injection - 2.5 iu - viral vaccines: rabiesvaccines

European Union - English - EMA (European Medicines Agency)

laboratorios syva, s.a.u. - inactivated bluetongue virus, serotype 1, strain alg2006/01 e1, inactivated bluetongue virus, serotype 4, strain btv-4/spa-1/2004, inactivated bluetongue virus, serotype 8, strain bel2006/01 - inactivated viral vaccines - cattle; sheep - for active immunisation of sheep to prevent viraemia and reduce clinical signs and lesions caused by bluetongue virus serotypes 1 and/or 8 and/or to reduce viraemia* and clinical signs and lesions caused by bluetongue virus serotype 4for active immunisation of cattle to prevent viraemia caused by bluetongue virus serotypes 1 and/or 8 and/or to reduce viraemia* caused by bluetongue virus serotype 4.

Philippines - English - FDA (Food And Drug Administration)

broadchem philippines biopharma corporation; distributor: broadchem philippines biopharma corporation - live attenuated canine distemper virus (cdv) , canine parainfluenza virus , canine adenovirus (cav) , canine parvovirus , inactivated leptospira interrogans ser. icterohaemorrhagiae , l. interrogans ser. canicola , l. kirschneri ser. grippotyphosa , l. interrogans ser. bratislava , rabies virus vaccine (vet.) - freeze-dried powder for injection (sc) - formulation: each dose (1 ml) contains: canine distemper virus (cdv bio 11/a strain)- 10^3.1 to 10^5.1 tcid50 canine parainfluenza type 2 virus (cpiv-2-bio 15 strain)-- 10^3.1 to 10^5.1 tcid50 canine adenovirus type 2 (cav-2-bio 13 strain)-10^3.6 to 10^5.3 tcid50 canine parvovirus type 2b (cpv-2b bio 12/b strain)-10^4.3 to 10^6.6 tcid50 leptospira interrogans ser. icterohaemorrhagiae (mslb 1089 strain)- >1:51 alr (gmt) ser. canicola (mslb 1090 strain)-- >1:51 alr (gmt) ser. bratislava (mslb 1088 strain)- >1:51 alr (gmt) leptospira kirschneri ser. grippotyphosa (mslb 1091 strain)- >1:40 alr (gmt) rabies virus (sad vnukovo-32 bio 16 strain)-> 2.0 iu tcid-tissue culture infect dose 50% gmt-geometric moon titre alr-agglutination lyuis reacties